BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Takeda’s neurodegenerative disease research. The companies will evaluate Takeda’s investigational therapeutics for potential treatment of neurodegenerative diseases in humans.
“Cerveau is focused on enhancing access to key technologies that we believe have the potential to advance human health,” said Rick Hiatt, Chief Executive Officer, Cerveau Technologies, Inc. “We are excited to welcome Takeda to our growing network of pharmaceutical partners and global production sites. Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a collaboration between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.